A web-based survey of United Kingdom sedation practice in the intensive care unit.

PURPOSE: The purpose of this work was to obtain a detailed perspective of sedation practice. Sedation included sedative and opioid choice, presence of local guidelines, and use of scoring systems. METHODS: A Web-based survey was designed. The aim was to gain sufficient detail of UK sedation while also being succinct enough to complete in 15 minutes. It was composed of relevant demographics, policy, sedative choice, and analgesia. The survey was piloted before launch. The investigators selected the intensive care unit (ICU) pharmacist as the respondent. RESULTS: One hundred fifty-seven ICUs responded. Eighty-nine (59%) reported use of sedation guidelines, 78% undertook sedation holds, and 87% use sedation scores. Only 42% used a daily sedation target. Seventy (43%) assess for delirium; 27 of those use a validated tool. Propofol (89%) use was common, followed by midazolam (49%). Morphine (49%), fentanyl (34%), and alfentanil (34%) were the most frequently used opioids. CONCLUSION: This survey confirmed expected variation in UK sedation practice. Recognized strategies such as target sedation score and sedation policy are underused. A 43% uptake in delirium screening suggests that larger engagement is required to meet national standards.

Management of long-term hypothyroidism: a potential marker of quality of medicines reconciliation in the intensive care unit.

OBJECTIVE: Significant errors can be made during medication prescribing, dispensing and administration. One source of error and potential for harm is unintentional omission. Medicines reconciliation seeks to reduce the impact of this between transfer of care. In long-term hypothyroidism, patients are dependent upon levothyroxine and there are few contraindications to its prescription. We considered levothyroxine prescription in long-term hypothyroidism as a marker of medicines reconciliation on admission and during stay in the intensive care unit (ICU). METHODS: A retrospective chart review was undertaken in a tertiary referral university ICU with all patients who were receiving long-term levothyroxine therapy identified. Notes were reviewed for the presence of thyroid-replacement prescription and for thyroid function tests, in addition to demographic, length of stay and mortality data. KEY FINDINGS: Thyroid-replacement therapy was not prescribed for more than 7 days in 23/133 (17.3%) patients and omitted entirely in three patients. A further 28/133 (21.1%) patients were intolerant of enteral feeding for more than 7 days and were thus unable to have oral levothyroxine administered. None of these patients received parenteral therapy. Thyroid function tests were performed in 104/133 (78.2%) patients. CONCLUSIONS: Prescription of chronic therapy, in this case thyroid-replacement therapy, was inadequate. This highlights the need for a progressive medicines-reconciliation process embedded within the daily ICU programme.

Adverse events and clinical outcome associated with drotrecogin alfa-activated: a single-center experience of 498 patients over 8 years.

PURPOSE: Licensed in 2002 for severe sepsis, drotrecogin alfa-activated (DAA) remains a much debated therapy particularly with respect to outcomes and a potentially increased risk of serious bleeding events (SBEs). Recent publications have suggested a significantly increased incidence of SBEs and death in those with baseline bleeding risks (BBRs). Our center is one of the highest prescribers of DAA worldwide; we describe our experience of SBEs and other clinical outcomes. METHODS: Prospectively collected data using a clinical guideline audit tool and database to track outcome and adverse events of DAA-treated severe sepsis patients were analyzed. RESULTS: Four hundred ninety-eight patients received DAA over an 8-year period. Hospital, critical care, and 28-day mortalities were 46.2%, 39.6%, and 35.1%, respectively. Contraindications were identified for 40 (8.0%) patients, of whom 24 (4.8%) had BBRs. Hospital mortality was 47.5% (19/40) for patients with any contraindication and 45.8% (11/24) for those with a BBR. Seventy-six (15.3%) bleeding events were reported; 22 (4.4%) were considered serious. Hospital mortality was 60.5% for patients with any bleeding event and 77.3% for those with SBEs. CONCLUSIONS: This large single-center case series demonstrates that DAA has an incidence of SBEs similar to initial clinical trials. As expected, SBEs were associated with a poor outcome.